The LINFU® U.S. Registry for the Detection of Asymptomatic Pancreatic Ductal Adenocarcinoma

Part of paid clinical trials in New York, New York.

Sponsor
Adenocyte, LLC
Study ID
NCT06157671
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 90 Years
Healthy Volunteers
Not accepted

Study Details

Adenocyte has developed LINFU®, (Low Intensity Non-Focused Ultrasound excitation of the pancreas) as a method of identifying early, asymptomatic pancreatic cancer and its noninvasive precancerous lesions. The test involves ultrasound and an analysis of pancreatic juice. A neural network-based computer-assisted system may be utilized to enhance the analysis. Patients enrolled are being screened for pancreatic cancer because they have known risk factors (i.e. smoking, diabetes, chronic pancreatitis, family history of pancreatic cancer, or certain genetic syndromes).

Key Dates

Start date
Jan 31, 2024
Status verified
Mar 2025
Primary completion
Jan 1, 2030
Completion
Jun 1, 2030

Study Design

Enrollment
1,000 participants (estimated)

Arms

  • Arm: Patients at increased risk for developing pancreatic cancer
    Patients being screened for pancreatic cancer because they have known risk factors (i.e. smoking, diabetes, chronic pancreatitis, family history of pancreatic cancer, or certain genetic syndromes) and are undergoing other imaging diagnostic tests to determine if they have pancreatic cancer

Primary Outcome Measure

The number of pancreatic ductal adenocarcinomas and their noninvasive precursor lesions identified only with LINFU® will be compared to standard screening methods [ Time Frame: 5 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
Manhattan Endoscopy CenterNew YorkNew York10017-

Find similar trials in New York, NY

By condition
Pancreatic cancer
By specialty
OncologyGI oncology
By research site
Manhattan Endoscopy Center· New York, NY

Related Studies